DOCS vs. TMDX, NUVL, IMVT, SEM, ALPN, MDGL, KRYS, RDNT, ALKS, and PRGO
Should you be buying Doximity stock or one of its competitors? The main competitors of Doximity include TransMedics Group (TMDX), Nuvalent (NUVL), Immunovant (IMVT), Select Medical (SEM), Alpine Immune Sciences (ALPN), Madrigal Pharmaceuticals (MDGL), Krystal Biotech (KRYS), RadNet (RDNT), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "medical" sector.
Doximity (NASDAQ:DOCS) and TransMedics Group (NASDAQ:TMDX) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability, community ranking and valuation.
Doximity has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Doximity, indicating that it is currently the more affordable of the two stocks.
Doximity has a net margin of 29.39% compared to TransMedics Group's net margin of -3.43%. Doximity's return on equity of 16.08% beat TransMedics Group's return on equity.
In the previous week, Doximity had 31 more articles in the media than TransMedics Group. MarketBeat recorded 39 mentions for Doximity and 8 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.92 beat Doximity's score of 0.48 indicating that TransMedics Group is being referred to more favorably in the news media.
Doximity has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500.
TransMedics Group received 36 more outperform votes than Doximity when rated by MarketBeat users. Likewise, 54.78% of users gave TransMedics Group an outperform vote while only 41.32% of users gave Doximity an outperform vote.
Doximity currently has a consensus price target of $28.73, indicating a potential upside of 2.49%. TransMedics Group has a consensus price target of $119.00, indicating a potential downside of 13.76%. Given Doximity's higher possible upside, equities research analysts clearly believe Doximity is more favorable than TransMedics Group.
87.2% of Doximity shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 39.4% of Doximity shares are owned by insiders. Comparatively, 7.0% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Doximity beats TransMedics Group on 10 of the 18 factors compared between the two stocks.
Get Doximity News Delivered to You Automatically
Sign up to receive the latest news and ratings for DOCS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Doximity Competitors List
Related Companies and Tools
